Oruka Therapeutics, Inc. (ORKA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $69.00: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum.
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for psoriasis and other inflammatory/immunology indications. Its two lead programs, ORKA-001 (IL-23p19 targeting) and ORKA-002 (IL-17A/F targeting), are in Phase 1/2... Read more
Sell if holding. Engine safety override at $69.00: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.2/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.80, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductORKA-001 and ORKA-00210-K Item 1A: 'We are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $69.00: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $64.17. Score 5.2/10, moderate confidence.
Take-profit target: $119.26 (+72.8% upside). Prior stop was $64.17. Stop-loss: $64.17.
Concentration risk — Product: ORKA-001 and ORKA-002; Quality below floor (1.6 < 4.0).
Oruka Therapeutics, Inc. trades at a P/E of N/A (forward -26.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover ORKA with a consensus score of 4.4/5. Average price target: $137.
What does Oruka Therapeutics, Inc. do?Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for...
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for psoriasis and other inflammatory/immunology indications. Its two lead programs, ORKA-001 (IL-23p19 targeting) and ORKA-002 (IL-17A/F targeting), are in Phase 1/2 clinical trials; the company has no approved products or product revenues.